MANGOCEUTICALS, INC.

For the period ended Mar 31, 2025. Filed May 15, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 15, 2025

MGRX$0.20+1.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 6. Exhibits

The following exhibits are filed herewith or incorporated by reference herein:

Filed/ · Incorporated by Reference
Exhibit · Description of · Furnished · Filing · File
Number	Exhibit	Herewith	Form	Exhibit	Date	Number
3.1	Amendment to Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of Mangoceuticals, Inc., submitted to the Secretary of State of Texas on March 17, 2025		8-K	3.3	3/19/2025	001-41615
3.2	Certificate of Designations of Mango & Peaches Corp., Establishing the Designations, Preferences, Limitations, and Relative Rights of Its Series A Super Majority Voting Preferred Stock, filed with the Secretary of State of Texas on January 9, 2025		8-K	3.1	1/15/2025	001-41615
10.1	Debt Conversion Agreement dated January 15, 2025, between Mangoceuticals, Inc. and Mill End Capital Ltd.		8-K	10.1	1/21/2025	001-41615
10.2#	Consulting Agreement dated January 15, 2025, between Mangoceuticals, Inc. and Antonios “Tony” Isaac		8-K	10.2	1/21/2025	001-41615
10.3	August 27, 2024, Payment Plan Letter Agreement between Mangoceuticals, Inc. and Barstool Sports, Inc. relating to $516,250 of outstanding debt		8-K	10.1	1/31/2025	001-41615
10.4€	January 10, 2025, Debt Purchase Agreement, between MAAB Global and Barstool Sports Inc.		8-K	10.2	1/31/2025	001-41615
10.5	First Amendment to Payment Plan Letter Agreement between Mangoceuticals, Inc. and MAAB Global, dated January 27, 2025		8-K	10.3	1/31/2025	001-41615
10.6	Assignment, Assumption and Novation Agreement dated January 30, 2025, by and among Mangoceuticals, Inc., as assignor, Mango & Peaches Corp., as assignee, and Epiq Scripts, LLC (MSA)		8-K	10.4	1/31/2025	001-41615
10.7	Assignment, Assumption and Novation Agreement dated January 30, 2025, by and among Mangoceuticals, Inc., as assignor, Mango & Peaches Corp., as assignee, and Epiq Scripts, LLC (Consulting Agreement)		8-K	10.5	1/31/2025	001-41615
10.8	LT Global Practice Management Service Agreement dated January 28, 2025, between Mangoceuticals, Inc. and LT Global Practice Management		8-K	10.6	1/31/2025	001-41615
10.9	Master Distribution Agreement dated January 30, 2025, between Propre Energie Inc, as supplier, and Mangoceuticals, Inc., as distributor		8-K	10.7	1/31/2025	001-41615
10.10	Form Common Stock Subscription Agreement (February 2025)		8-K	10.1	2/7/2025	001-41615
10.11#	First Amendment to Employment Agreement dated February 6, 2025, between Mangoceuticals, Inc. and Amanda Hammer		8-K	10.2	2/7/2025	001-41615
10.12	February 11, 2025, Letter Amending April 24, 2024 Patent Purchase Agreement, between Mangoceuticals, Inc. and Intramont Technologies		8-K	10.1	2/12/2025	001-41615
10.13	Form of Common Stock Subscription Agreement (February 2025)		8-K	10.2	2/12/2025	001-41615
10.14	Second Amendment to the Mangoceuticals, Inc. 2022 Equity Incentive Plan		8-K	10.1	3/19/2025	001-41615
10.15	Second Amended and Restated Mangoceuticals, Inc. 2022 Equity Incentive Plan		8-K	10.2	3/19/2025	001-41615
10.16	Master Distribution Agreement dated March 24, 2025, between Navy Wharf, Ltd, as supplier, and Mangoceuticals, Inc., as distributor		8-K	10.1	3/25/2025	001-41615
10.17	Form of Securities Purchase Agreement dated April 11, 2025, relating to the sale of 100 shares of Series B Convertible Preferred Stock		8-K	10.1	4/17/2025	001-41615
10.18	Promissory Note dated April 15, 2025, evidencing $500,000 owed by Mangoceuticals, Inc. to Indigo Capital LP		8-K	10.2	4/17/2025	001-41615
10.19+	Intellectual Property Purchase Agreement dated April 24, 2025, by and between Mangoceuticals, Inc., as purchaser and Smokeless Technology Corp., as seller		8-K	10.1	4/25/2025	001-41615
10.20+	Consulting Agreement dated April 24, 2025, between Mangoceuticals, Inc. and Strategem Solutions, Inc.		8-K	10.2	4/25/2025	001-41615
10.21+	First Amendment to Amended and Restated Executive Employment Agreement dated April 24, 2025 and effective April 1, 2025, by and between Mangoceuticals, Inc. and Jacob Cohen		8-K	10.3	4/25/2025	001-41615
10.22#	Promissory Note dated May 2, 2025 in the principal amount of $100,000, between Mangoceuticals, Inc., borrower and The Tiger Cub Trust, lender		8-K	10.1	5/6/2025	001-41615
10.23*	Master Distribution Agreement dated May 14, 2025, between PrevenTech Solutions, LLC, as distributor, and Mangoceuticals, Inc., as supplier	X
31.1*	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act	X
31.2*	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act	X
32.1**	Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act	X
32.2**	Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act	X
101.INS*	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document	X
101.SCH*	XBRL Taxonomy Extension Schema Document	X
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document	X
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document	X
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document	X
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document	X
104*	Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set	X

Filed herewith.

** Furnished herewith.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.